BAFF-targeting therapy, a promising strategy for treating autoimmune diseases.
Since B cell activating factor belonging to tumor necrosis factor (TNF) family (BAFF) has been identified as a critical factor for B cell maturation and survival, convincing evidence indicates that deregulation of BAFF is involved in pathogenesis of B cell related autoimmune diseases. Blockade of BAFF activity significantly improves the symptoms of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis both in animal models and clinical trials. Therefore, BAFF-targeting therapy is a promising approach to treat B cell related autoimmune diseases.
Sun
Jian
J
Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 30072, PR China. jsun@public3.bta.net.cn
Lin
Zhou
Z
Feng
Jiannan
J
Li
Yan
Y
Shen
Beifen
B
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D053264:B-Cell Activating Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects*; D016896:Treatment Outcome
D053264:B-Cell Activating Factor; D007166:Immunosuppressive Agents